RARA CRAFT DATABASE for FDA Medical Devices
510(k)K170280

FDA DEVICE FACTS

Smith & Nephew SURESHOT Distal Targeting System V4.0

Smith & Nephew, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEApril 28, 2017PRODUCT CODEOLO

Indications for use

The Smith & Nephew SURESHOT™ Targeting System is intended to be an intraoperative image guided localization system. It is a computer assisted orthopedic surgery tool to aid the surgeon with drill positioning for screws during intramedullary nail implantation. It provides information to the surgeon that is used to place surgical instruments during surgery utilizing intraoperatively obtained electromagnetic tracking data. The Smith & Nephew SURESHOT™ Targeting System is indicated for long bone fractures treated with intramedullary nails in which the use of stereotactic surgery may be appropriate.

Comparison to Technological Characteristics with the Predicate Device Device comparisons described in this premarket notification demonstrated that the proposed SURESHOT™ Targeting System is equivalent to the legally marketed predicate devices cleared in the below table with regard to intended use, indications for use, and performance characteristics.

The subject devices feature characteristics as previously cleared in K130748 with the primary differences being additional software features which include the ability to target for the TRIGEN META-TAN Nail (previously cleared in K092748), the ability for on screen rotation using the SURESHOT™ Targeter, additional languages of the graphical user interface (for international users), updates to the graphical user interface, and updates to the Launcher program

Summary of Pre-Clinical Testing Software verification and validation testing was completed in line with FDA's guidance document entitled, “General Principles of Software Validation; Final Guidance for Industry and FDA Staff,” dated January 11, 2002. Preclinical testing included the following tests:  12.102 Software Validation and Verification Report  12.201 Deployment Distal Targeting Software  12.301 Workflow and System Settings  12.302 Tool Connections  12.303 Sleeve Selection  12.304 Implant Selection  12.305 Drilling Screen  12.306 Hardware Failure  12.307 Drill Depth Measurement  12.308 Targeting Calculations META  12.309 Targeting Calculations TAN/FAN  12.310 Targeting Calculations Humeral  12.311 Targeting Calculations Field Check  12.312 Targeting Calculations META-TAN  12.313 Translations Chinese  12.314 Translations English  12.315 Translations French  12.316 Translations German  12.317 Translations Italian  12.318 Translations Japanese  12.319 Translation Portuguese  12.320 Translation Finnish  12.321 Translation Spanish  12.322 Nail Rotation  12.323 View Selection  12.401 Customer Validation  12.402 Regression Test

A review of this testing has demonstrated that there are no new issues related to the safety and effectiveness of the subject device and the software will perform as intended as compared to the predicate. Clinical data was not needed to support the safety and effectiveness of the subject device.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 29, 2026